SCARLETRED Holding

Executive Summary

SCARLETRED Holding is an Austrian digital health company that leverages a proprietary AI-powered platform for remote monitoring and analysis of skin conditions. Founded in 2016 and headquartered in Vienna, the company addresses critical inefficiencies in dermatology and wound care by enabling standardized image capture and secure data transmission. Its technology serves three key segments: clinical trials (improving data quality and reducing site burden), telemedicine (facilitating specialist access for patients), and patient self-management (empowering individuals to track chronic conditions). With the global teledermatology market projected to grow at over 15% CAGR through 2030, SCARLETRED is well-positioned to capture value by replacing manual photography and subjective assessments with objective, AI-driven insights. The platform's ability to integrate into existing workflows and its focus on regulatory compliance make it a compelling solution for healthcare providers and pharmaceutical sponsors. The company has successfully piloted its platform with several European dermatology clinics and is now pursuing broader commercial deployment. Its value proposition lies in reducing clinical trial costs by up to 30% through remote monitoring and improving patient adherence via self-tracking features. SCARLETRED is currently seeking regulatory approvals for wound care applications and building strategic partnerships to scale its footprint. While the digital health landscape is competitive, the company's niche focus on dermatology and its strong IP portfolio differentiate it. Looking ahead, key milestones include regulatory clearances, partnership announcements, and a planned funding round to accelerate commercialization. SCARLETRED's technology has the potential to become the standard for skin condition monitoring in both clinical and research settings.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance for wound care monitoring platform60% success
• Q3 2026Strategic partnership with a top-10 pharmaceutical company for clinical trial imaging70% success
• Q4 2026Series A funding round of €5-10 million80% success